Market News / Story
SLS Stock’s 2-Week Rally Loses Steam: Retail Sees ‘Peanut Prices’ As Fresh AML Study Fuels Regal Hopes
Stocktwits ·
Stocktwits reports: Shares of Sellas Life Sciences (SLS) are on track to snap a two-week winning streak even as fresh leukemia research revived retail hopes for its cancer vaccine ahead of Regal’s final-analysis milestone. SLS stock fell 0.3% on Wednesday to $11.31, marking its third consecutive session of losses and leaving shares down 4% for the week. New AML Study Draws SLS Investors’ Attention A study published in Leukemia compared venetoclax-based therapy with hypomethylating agents…